EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
From Listening to Leading: Reimagining HEOR Through the Lens of Patient-Centred Evidence
Co-Founder & Director, MarksMan Healthcare
Dimple Dang CoFounder of MarksMan Healthcare is a strategic growth architect shaping the firms global footprint She forges highimpact collaborations leads business expansion and builds a talent ecosystem aligned with excellence Her leadership elevates credibility strengthens brand equity and positions MarksMan as a trusted strategic partner delivering value across global healthcare markets
Articles
Novel Developments in Drug Delivery Systems
Discovery of new active pharmaceutical compounds is no longer the only essential factor for therapeutic innovation clinical success increasingly depends on how effectively those agents are delivered to the intended site of action
Research Insights
In Situ Forming Hydrogels Based On Chitosan For Drug Delivery And Tissue Regeneration
Abstract In situ forming hydrogels with simple solgel transition are more practicable as injectable hydrogels for drug delivery and tissue regeneration Stateoftheart in situ gelling systems can easily and efficiently be formed by different mechanisms in situ Chitosan is a kind of natural polysaccharide that is widely exploited for biomedical applications
Case Studies
External Innovation Implementation Determinants and Performance Measurement: A Case Study from the Pharmaceutical Industry
Abstract With an increasing amount of externally sourced innovations a major success factor for innovationdependent industries such as the pharmaceutical industry is to successfully implement innovations from outside Existing frameworks emphasize creating a strong climate for implementation by developing the learning capabilities of the organization but the
Techno Trends
New Xolair® Treats Severe Chronic Rhinosinusitis with Nasal Polyps
Novartis has discovered a new Xolair indication for the treatment of severe Chronic Rhinosinusitis with Nasal Polyps CRSwNP for adults Xolair omalizumab is the first discovered treatment option for CRSwNP which specifically targets and blocks the growth
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Therapeutic Peptides
Rienzi Mosqueda is a dedicated writer specialising in life science, health, and pharma content. With a passion for clear, engaging writing, Rienzi provides fresh perspectives on each topic. His ability to simplify complex ideas makes the articles valuable for readers of all backgrounds. As an emerging voice, Rienzi Mosqueda is committed to sharing knowledge and sparking discussions through their impactful writing.
Allosteric Modulation: A Paradigm Shift in Pharmaceutical Innovation
Dr. Parth Sarthi Sen Gupta is a Computational Biologist specializing in computational drug and vaccine design, with a focus on allosteric modulation. He is an Associate professor in School of Biosciences and Bioengineering, D Y Patil International University. He has published more than 50 research articles and book chapter in reputed peer reviewed Journals. His research work on COVID19 has been highlighted by various national and international news agencies and recognized by World health organizations.
Why tier-2 and tier-3 cities are not included for clinical research
Co-Founder at DPHS Pvt. Ltd., Dr. Krutikesh Age is a researcher and a visionary committed towards propelling the field of clinical research and healthcare expansion in India. As the Co-founder of DPHS, Krutikesh manages varied key roles including Leadership, developing business and marketing strategies and Networking to name a few. It is through the deep understanding of clinical research and market dynamics that he has been instrumental in expanding the operations of DPHS in the past few years.
Envisioning the Biomanufacturing Facility of the Future
Merrilee is the Head of the BioContinuum™ Platform, driving the strategy and execution of Process Intensification Technologies, Software & Automation, and Analytics to meet the needs of biologics manufacturers. Throughout her 15 years at MilliporeSigma, she managed multiple product lines including clarification, aseptic, virus filtration, and Single Use & Systems.
The Regulatory Landscape for Nutraceuticals
Suresh Garg is the CMD and Founder of Zeon Life Sciences. He has over 30 years of extensive experience in the fields of nutrition, dairy products, healthcare, and nutraceuticals. Under his leadership, Zeon has become a pioneer in contract manufacturing for nutraceuticals and herbal goods. Owing to his passion and ability to thrive in a variety of sociocultural environments, Zeon has entered international markets.
press releasesRead more...
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
Roche announced today new twoyear data from the Phase IIIbIV SALWEEN study of Vabysmo faricimab presented at the th AsiaPacific Vitreoretina Society APVRS Congress in Australia
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
Simcere Zaiminga subsidiary of Simcere Pharmaceutical Group HK today announced that it has entered into an exclusive global licensing agreement with Roche for the development and commercialization
T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
TMAXIMUM PHARMACEUTICAL Inc TMAXIMUM today announced that its investigational allogeneic CART cell therapy MT has been granted Fast Track Designation FTD by the US Food and Drug Administration FDA for the treatment of recurrent glioblastoma
Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan in combination with pertuzumab has been approved in the European Union EU for the stline treatment of adult patients with unresectable or metastatic HERpositive breast cancer
RMIT and GonGlobal partner to replace IVF injections with inhaled medicines
RMIT University researchers are working with Melbourne company GonGlobal to develop an inhaled alternative to in vitro fertilisation IVF injections a change that could make treatment dramatically easier for patients
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Vertex Pharmaceuticals Incorporated Nasdaq VRTX today announced the successful completion of the acquisition of Crinetics Pharmaceuticals Inc Nasdaq CRNX a global pharmaceutical company focused
EventsRead more...
03 - 05
Sep 20265th MENA Congress for Rare Diseases 2026
Beach Rotana Hotel, Abu Dhabi,...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
LATEST NEWSRead more...
Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026
As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders
HUTCHMED Announces Approval of ATLED® (Fanregratinib) for FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
HUTCHMED has received conditional approval from Chinas National Medical Products Administration NMPA for ATLED fanregratinib to treat adults with advanced metastatic or unresectable intrahepatic cholangiocarcinoma ICC with FGFR fusion or rearrangement who have previously received systemic therapy
Osivax Enters into Collaboration with GC Biopharma to Develop Next-Generation Influenza Vaccine
Osivax and GC Biopharma have entered into a strategic collaboration to develop and commercialise a nextgeneration seasonal influenza vaccine designed to provide broader and more durable protection against a range of influenza strains
Cipla Enters into Agreement with SBP Group for HER2 bispecific ADC TQB2102
Cipla and Sino Biopharmaceutical SBP Group have entered into an exclusive licensing and supply agreement for Rolditamig Deuderuxtecan also known as TQB a HERtargeted bispecific antibodydrug conjugate ADC being developed for the treatment of cancer
Jazz Pharmaceuticals Announces Approval of Ziihera Regimens for Advanced HER2-Positive Gastroesophageal Cancer
Jazz Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved two Ziihera zanidatamabhriibased treatment regimens for the firstline treatment of adults with unresectable
BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients
BioCryst Pharmaceuticals has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORLADEYO berotralstat for the prevention of hereditary angioedema HAE attacks in children aged to under years
